Paraneoplastic neurologic disorders in small cell lung carcinoma

Neurology

Volumn 85, Issue 3, 2015, Pages 235-239

  Gozzard, Paul ^a   Woodhall, Mark ^a   Chapman, Caroline ^b   Nibber, Anjan ^a   Waters, Patrick ^a   Vincent, Angela ^a   Lang, Bethan ^a   Maddison, Paul ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIPHYSIN; GLUTAMATE DECARBOXYLASE 65; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; EATON LAMBERT SYNDROME; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; PARANEOPLASTIC NEUROLOGIC DISORDER; PARANEOPLASTIC NEUROPATHY; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSORY NEURONOPATHY; SMALL CELL LUNG CANCER; TUMOR BIOPSY; TUMOR DIAGNOSIS; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; HEK293 CELL LINE; LUNG NEOPLASMS; MIDDLE AGED; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; SMALL CELL LUNG CARCINOMA;

AGED; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HEK293 CELLS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; PROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA;

EID: 84937692270     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001721     Document Type: Article

References (24)

1. Gozzard P, Maddison P. Which antibody and which cancer in which paraneoplastic syndromes? Pract Neurol 2010; 10: 260-270
2. Giometto B, Grisold W, Vitaliani R, et al. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol 2010; 67: 330-335
3. Office for National Statistics. Cancer Statistics Registrations: Registrations of Cancer Diagnosed in 2006.England; 2008
4. Benatar M, Blaes F, Johnston I, et al. Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line. J Neuroimmunol 2001; 113: 153-162
5. Elrington GM, Murray NM, Spiro SG, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry 1991; 54: 764-767
6. Wirtz PW, Lang B, Graus F, et al. P/Q-Type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer. J Neuroimmunol 2005; 164: 161-165
7. Payne M, Bradbury P, Lang B, et al. Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer. J Thorac Oncol 2010; 5: 34-38
8. Irani SR, Gelfand JM, Al-Diwani A, Vincent A. Cellsurface CNS autoantibodies: clinical relevance and emerging paradigms. Ann Neurol 2014; 76: 168-184
9. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75: 1135-1140
10. Iwasa K, Pinto A, Vincent A, et al. LEMS IgG binds to extracellular determinants on N-Type voltage-gated calcium channels, but does not reduce VGCC expression. Ann NY Acad Sci 2003; 998: 196-199
11. Shillito P, Molenaar PC, Vincent A, et al. Acquired neuromyotonia: evidence for autoantibodies directed against K1 channels of peripheral nerves. Ann Neurol 1995; 38: 714-722
12. Malter MP, Helmstaedter C, Urbach H, et al. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 2010; 67: 470-478
13. Chapman CJ, Thorpe AJ, Murray A, et al. Immunobiomarkers in small cell lung cancer: potential early cancer signals. Clin Cancer Res 2011; 17: 1474-1480
14. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-Associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010; 133: 2734-2748
15. Irani SR, Bera K, Waters P, et al. N-methyl-D-Aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly nonparaneoplastic disorder of both sexes. Brain 2010; 133: 1655-1667
16. Bilimoria PM, Bonni A. Cultures of cerebellar granule neurons. CSH Protoc 2008; 2008: pdb.prot5107. doi: 10.1101/pdb.prot5107
17. Titulaer MJ, Klooster R, Potman M, et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol 2009; 27: 4260-4267
18. Sabater L, Höftberger R, Boronat A, Saiz A, Dalmau J, Graus F. Antibody repertoire in paraneoplastic cerebellar degeneration and small cell lung cancer. PLoS One 2013; 8: e60438
19. Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1995; 58: 85-87
20. Jeffery OJ, Lennon VA, Pittock SJ, Gregory JK, Britton JW, McKeon A. GABAB receptor autoantibody frequency in service serologic evaluation. Neurology 2013; 81: 882-887
21. Sabater L, Titulaer M, Saiz A, Verschuuren J, Güre AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 2008; 70: 924-928
22. Zhai RG, Bellen HJ. The architecture of the active zone in the presynaptic nerve terminal. Physiology 2004; 19: 262-270
23. Chalk CH, Murray NM, Newsom-Davis J, et al. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990; 40: 1552-1556
24. Sillevis Smitt P, Grefkens J, de Leeuw B, et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 2002; 249: 745-753